Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience

Murat Özbalak,Metban Güzel Mastanzade,Özden Özlük,Tarık Onur Tiryaki,Simge Erdem,Ezgi Pınar Özbalak,Tuğrul Elverdi,İpek Yönal Hindilerden,Ali Yılmaz Altay,Gülçin Yeğen,Ahmet Emre Eşkazan,Muhlis Cem Ar,Mustafa Nuri Yenerel,Teoman Soysal,Meliha Nalçacı,Burhan Ferhanoğlu,Sevgi Kalayoğlu Beşışık

Turkish journal of haematology : official journal of Turkish Society of Haematology（2022）

引用 0|浏览11

暂无评分

摘要

RED has an ORR similar to that of MAB. However, PFS rates were worse in the RED cohort. Additionally, CNS relapse ratio was a major concern for our RED cohort. Large prospective controlled studies and real-life data with longer follow-up are needed to document the non-inferiority of RED compared to MAB.

查看译文

关键词

Redditux,Rituximab,Biosimilar,Diffuse large B-cell lymphoma,Non-Hodgkin lymphoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要